The Company has developed a proprietary, next-generation medical imaging platform providing high-resolution, non-ionizing functional and anatomical imaging in real time. The technology is commercially established in the research market with significant potential expansion into much larger clinical applications, initially targeting vascular imaging followed by breast imaging and diagnostics.

Unlike many emerging MedTech opportunities, this is not a concept-stage or pre-revenue company. The platform has generated $5M+ in historical commercial revenue, with approximately 25 imaging systems deployed in the U.S. and internationally and adoption by academic, pharmaceutical and research customers.

Approximately $15M has already been invested in R&D and platform development, supported in significant part by non-dilutive government research funding, commercial system sales and invested capital. This substantial prior investment, installed base and commercial validation provide a strong foundation for the Company's next stage of growth.

The business model centers on high-value imaging systems and accessories, with additional potential recurring revenue from software and analytics, upgrades, service and support. Management's current model assumes approximately $300K ASP for research systems and $450K for future clinical systems.

INVESTMENT HIGHLIGHTS

• $5M+ historical commercial revenue
• Approximately 25 systems deployed
• Approximately $15M invested in R&D and platform development
• Significant non-dilutive government-supported R&D
• Extensive independent scientific and academic validation
• Established academic, pharmaceutical and research-market adoption
• Broad international intellectual-property protection
• Proprietary functional + anatomical imaging platform
• Existing commercial foundation for clinical expansion
• Potential recurring software, upgrade and service revenue
• ~$300K research / ~$450K future clinical system ASPs

DEFINED PATH TO CLINICAL COMMERCIALIZATION

Management is pursuing a phased strategy designed to create multiple potential value-inflection points:

Research Commercialization → Vascular Clinical Market → Breast Imaging Platform

Rather than relying exclusively on the longer regulatory pathway associated with breast screening, management intends to pursue vascular imaging as the nearer-term clinical entry point, leveraging capabilities already inherent in the existing platform. The longer-term strategy is an integrated breast-imaging platform combining functional and anatomical assessment.

This approach allows the Company to build upon an existing revenue-generating research business while pursuing progressively larger clinical opportunities.

LARGE ADDRESSABLE MARKETS

Management estimates:

Breast Imaging: ~$15–20B TAM
Vascular Imaging: $5B+ TAM
Research & Pharmaceutical Imaging: $1B+ TAM

The existing research business therefore represents a commercially validated foundation for expansion into substantially larger clinical markets.

$5 MILLION GROWTH INVESTMENT

The Company is seeking approximately $5M in growth capital to advance clinical and regulatory development, vascular commercialization, continued breast-platform development, research-market expansion, manufacturing scale-up and commercialization infrastructure.

For the right investor, this represents an opportunity to participate after approximately $15M has already been invested in technology development, $5M+ in commercial revenue has been generated and approximately 25 systems have been deployed—but before the Company's planned expansion into significantly larger clinical markets.

The opportunity may be particularly attractive to medical-device and imaging strategics, healthcare-focused investment groups, family offices and MedTech investors seeking a defensible technology platform with demonstrated commercial validation and significant clinical-market upside.